REPLIGEN CORP Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
REPLIGEN CORP (RGEN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $62.76 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-07-29
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $65.80, a 18.16% decline year-over-year.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $80.40, a 17.63% decline year-over-year.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $97.61, a 9.37% increase year-over-year.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $89.25, a 11.62% increase year-over-year.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $73.38, a 16.61% decline from fiscal 2024.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $88.00, a 4.30% increase from fiscal 2023.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $84.37, a 3.47% decline from fiscal 2022.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $87.40, a 0.69% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $62.76 10-Q · filed 2026-07-29 | |||||||
| 2026-03-31 | $65.80 10-Q · filed 2026-05-06 | |||||||
| 2025-12-31 | $73.38 10-K · filed 2026-02-26 | |||||||
| 2025-09-30 | $72.94 10-Q · filed 2025-11-04 | |||||||
| 2025-06-30 | $73.61 10-Q · filed 2026-07-29 | |||||||
| 2025-03-31 | $80.40 10-Q · filed 2026-05-06 | |||||||
| 2024-12-31 | $88.00 10-K · filed 2026-02-26 | |||||||
| 2024-09-30 | $89.09 10-Q · filed 2025-11-04 | |||||||
| 2024-06-30 | $93.65 10-Q · filed 2025-08-07 | |||||||
| 2024-03-31 | $97.61 10-Q · filed 2025-04-29 | |||||||
| 2023-12-31 | $84.37 10-K · filed 2026-02-26 | |||||||
| 2023-09-30 | $85.70 10-Q/A · filed 2024-11-18 | |||||||
| 2023-06-30 | $86.30 10-Q/A · filed 2024-11-18 | |||||||
| 2023-03-31 | $89.25 10-Q/A · filed 2024-11-18 | |||||||
| 2022-12-31 | $87.40 10-K · filed 2025-03-14 | |||||||
| 2022-09-30 | $76.64 10-Q/A · filed 2024-11-18 | |||||||
| 2022-06-30 | $76.64 10-Q/A · filed 2024-11-18 | |||||||
| 2022-03-31 | $79.96 10-Q/A · filed 2024-11-18 | |||||||
| 2021-12-31 | $88.01 10-K/A · filed 2024-11-18 | |||||||
| 2021-09-30 | $88.01 10-Q · filed 2022-11-01 | |||||||
| 2021-06-30 | $86.96 10-Q · filed 2022-08-02 | |||||||
| 2021-03-31 | $92.35 10-Q · filed 2022-04-27 | |||||||
| 2020-12-31 | $53.06 10-K · filed 2023-02-22 | |||||||
| 2020-09-30 | $48.13 10-Q · filed 2021-10-28 | |||||||
| 2020-06-30 | $46.56 10-Q · filed 2021-07-27 | |||||||
| 2020-03-31 | $41.77 10-Q · filed 2021-05-04 | |||||||
| 2019-12-31 | $31.27 10-K · filed 2022-02-17 | |||||||
| 2019-09-30 | $30.07 10-Q · filed 2020-11-05 | |||||||
| 2019-06-30 | $30.07 10-Q · filed 2020-07-30 | |||||||
| 2019-03-31 | $30.21 10-Q · filed 2020-05-06 | |||||||
| 2018-12-31 | $18.90 10-K · filed 2021-02-24 | |||||||
| 2018-09-30 | $18.56 10-Q · filed 2019-10-31 | |||||||
| 2018-06-30 | $18.41 10-Q · filed 2019-08-01 | |||||||
| 2018-03-31 | $18.27 10-Q · filed 2019-05-09 | |||||||
| 2017-12-31 | $16.94 10-K · filed 2020-02-26 | |||||||
| 2017-09-30 | $16.94 10-Q · filed 2018-11-01 | |||||||
| 2017-06-30 | $16.94 10-Q · filed 2018-08-02 | |||||||
| 2017-03-31 | $16.46 10-Q · filed 2018-05-08 | |||||||
| 2016-12-31 | $14.16 10-K · filed 2019-03-01 | |||||||
| 2016-09-30 | $13.55 10-Q · filed 2017-11-09 | $20.80 10-Q · filed 2016-11-03 | ||||||
| 2016-06-30 | $13.55 10-Q · filed 2017-08-03 | $20.11 10-Q · filed 2016-08-04 | ||||||
| 2016-03-31 | $13.49 10-Q · filed 2017-05-04 | $19.57 10-Q · filed 2016-05-05 | ||||||
| 2015-12-31 | $16.05 10-K · filed 2018-02-22 | $22.45 10-K · filed 2016-02-25 | ||||||
| 2015-09-30 | $22.41 10-Q · filed 2016-11-03 | |||||||
| 2015-06-30 | $21.83 10-Q · filed 2016-08-04 | |||||||
| 2015-03-31 | $19.67 10-Q · filed 2016-05-05 | |||||||
| 2014-12-31 | $9.45 10-K · filed 2017-02-23 | $4.41 10-K · filed 2015-03-17 | ||||||
| 2014-09-30 | $11.12 10-Q · filed 2015-11-05 | |||||||
| 2014-06-30 | $10.85 10-Q · filed 2015-08-06 | |||||||
| 2014-03-31 | $10.58 10-Q · filed 2015-05-08 | |||||||
| 2013-12-31 | $4.31 10-K · filed 2016-02-25 | |||||||
| 2013-09-30 | $4.19 10-Q · filed 2014-11-07 | |||||||
| 2013-06-30 | $3.84 10-Q · filed 2014-08-11 | |||||||
| 2013-03-31 | $3.26 10-Q · filed 2014-05-09 | |||||||
| 2012-12-31 | $3.62 10-K · filed 2015-03-17 | |||||||
| 2012-09-30 | $3.63 10-Q · filed 2013-11-08 | |||||||
| 2012-06-30 | $3.62 10-Q · filed 2013-08-07 | |||||||
| 2012-03-31 | $2.30 10-Q · filed 2013-05-07 | |||||||
| 2011-12-31 | $1.89 10-K · filed 2013-03-15 | |||||||
| 2011-09-30 | $2.21 10-Q · filed 2012-11-08 | |||||||
| 2011-06-30 | $2.64 10-Q · filed 2012-08-09 | |||||||
| 2011-03-31 | $2.11 10-K · filed 2013-03-15 | |||||||
| 2010-12-31 | $1.95 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |